At the end of the 299th MPC meeting on Thursday, the committee was unanimous in its decision to hold all parameters and thus decided to retain the MPR at 27.50 per cent, the asymmetric corridor ...

Findings from the phase 1b Beamion LUNG-1 trial showed an objective response rate of 71% in NSCLC patients treated with zongertinib. The Food and Drug Administration (FDA) has granted Priority ...

A follow-up question was not answered. MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible ...

Rep. Natalie Zeleznikar, R-Fredenberg Township, is sponsor of the bill for the grant program. MPR News helps you turn down the noise and build shared understanding. Turn up your support for this ...